In contrast, for patients with low or medium-risk NB, the low-intensity treatments after tumor resection may not effectively break TSPYL5-mediated p53 suppression, causing an observable effect of TSPYL5 on the prognosis of the patients. The gene discussed is TSPYL5; the disease is neuroblastoma.